Join to View Full Profile
44 Binney StreetDana-Farber Cancer InstituteBoston, MA 02115
Phone+1 617-632-4524
Dr. Pomerantz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2001 - 2004
Stanford University School of MedicineClass of 2001
Certifications & Licensure
MA State Medical License 2004 - 2027
NH State Medical License 2024 - 2026
Clinical Trials
- Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer Start of enrollment: 2003 Mar 01
- International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Roles: Contact
Publications & Presentations
PubMed
- Outcome of Subsequent Therapies AfterLu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience.Meryam Losee, Michael Kavanaugh, Mofei Liu, Nuno Borges, Veronica Haberman
The Prostate. 2025-03-18 - Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.Jonathan Mitchell, Niedzica Camacho, Patrick Shea, Konrad H Stopsack, Vijai Joseph
Nature Communications. 2025-02-19 - The Germline and Somatic Origins of Prostate Cancer Heterogeneity.Takafumi N Yamaguchi, Kathleen E Houlahan, Helen Zhu, Natalie Kurganovs, Julie Livingstone
Cancer Discovery. 2025-02-13
Journal Articles
- Association of Genetic Variation of the Six Gene Prognostic Model for Castration‐Resistant Prostate Cancer with SurvivalMark M Pomerantz, Philip W Kantoff, The Prostate
- A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate CancerChristopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate
Press Mentions
- Incontinence and Impotence: Man Hopes to Create Discussion About Prostate CancerNovember 2nd, 2020
Prostate Cancer Metastasizes by Hijacking a Developmental Epigenetic ProgramSeptember 15th, 2020- Reddit Comic About Canadian Man's Positive Pregnancy Test Sparks Cancer DiagnosisNovember 8th, 2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
